One final consequence of our findings is related to proposed immunotherapy using dendritic cells isolated from CML patients.55, 56, 57 Although there are evidences that the immune system can potentially eliminate CML cells, particularly imatinib-resistant BCR–ABL1-positive stem cells, a note of caution should be added to the use of autologous dendritic cells, as patients in advanced phase of CML express low levels of WASP and, therefore, are likely to present impaired immunological synapses and consequent deficiency in antigen presentation. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.